Semler Scientific Inc (NASDAQ:SMLR) intends to report and discuss its 4Q and fiscal 2014 earnings results on February 6. Analysts expect SMLR to post losses for both periods. However, the company is cited as having a powerful marketing strategy for its only product known as FloChec. Investors have been betting…
Pluristem Therapeutics Inc. (NASDAQ:PSTI) soared in the market by double percentage gains after equity research firm Acceleron echoed bullish sentiments on the company. The research firm on a research note to investors upgraded the stock to a ‘Buy’ with a share price target of $21. The research firm maintains that Pluristem Therapeutics stock should trade at a 745%…